Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
07 Sep 2020
Historique:
entrez: 10 9 2020
pubmed: 11 9 2020
medline: 11 9 2020
Statut: epublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in individual's immune memory antibody repertoires linked to trajectories of disease severity from the longitudinal analysis also including anti-spike protein antibodies. By applying a machine-learning-based strategy, we developed a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival. These results provide a basis for understanding the roles of memory B-cell repertoires in COVID-19-related symptoms as well as a predictive tool for monitoring its clinical severity.

Identifiants

pubmed: 32908997
doi: 10.1101/2020.09.04.20187088
pmc: PMC7480049
pii:
doi:

Types de publication

Preprint

Langues

eng

Commentaires et corrections

Type : UpdateIn

Références

Crit Rev Immunol. 2018;38(1):17-62
pubmed: 29717662
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Autoimmun Rev. 2020 Aug;19(8):102597
pubmed: 32535093
J Clin Invest. 2015 Jun;125(6):2228-33
pubmed: 25893595
Nat Med. 1997 Dec;3(12):1394-7
pubmed: 9396611
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Chin Med J (Engl). 2020 May 5;133(9):1087-1095
pubmed: 32358325
Nat Rev Microbiol. 2011 Apr;9(4):254-64
pubmed: 21407242
Sci Transl Med. 2015 Apr 1;7(281):281ra43
pubmed: 25834109
Immunity. 2015 May 19;42(5):805-13
pubmed: 25992857
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Science. 2020 May 8;368(6491):638-642
pubmed: 32234804
Science. 2015 Jun 5;348(6239):aaa0698
pubmed: 26045439
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Rev Dis Primers. 2018 Aug 2;4(1):11
pubmed: 30072738
Immunol Rev. 2018 May;283(1):138-149
pubmed: 29664566
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Nat Rev Immunol. 2009 Apr;9(4):246-58
pubmed: 19319143
Cancer Cell. 2019 Oct 14;36(4):418-430.e6
pubmed: 31588021
Cancer Res. 2010 Dec 15;70(24):10202-12
pubmed: 21159642
Immunity. 2015 Jul 21;43(1):132-45
pubmed: 26187412
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15193-15199
pubmed: 32522874
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Nat Rev Immunol. 2020 Jul;20(7):442-447
pubmed: 32528136
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8227-32
pubmed: 9653169
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Cell. 2020 Jul 23;182(2):317-328.e10
pubmed: 32526205
Science. 2019 Nov 1;366(6465):599-606
pubmed: 31672891
Nat Rev Rheumatol. 2020 Aug;16(8):413-414
pubmed: 32499548
Ann Neurol. 2006 Mar;59(3):499-503
pubmed: 16502434
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Limin Wang (L)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892.
These authors contributed equally.

Julián Candia (J)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892.
These authors contributed equally.

Lichun Ma (L)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892.
These authors contributed equally.

Yongmei Zhao (Y)

CCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Frederick National Laboratory for Cancer Research, 8560 Progress Drive, Frederick, Maryland 21701.
These authors contributed equally.

Luisa Imberti (L)

CREA Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.

Alessandra Sottini (A)

CREA Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.

Kerry Dobbs (K)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Andrea Lisco (A)

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Irini Sereti (I)

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Helen C Su (HC)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Luigi D Notarangelo (LD)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Xin Wei Wang (XW)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892.
Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892.
Lead Contact.

Classifications MeSH